EDGAR·FLOW

Instil Bio, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 28/100
What the filing says
Instil Bio reported Q3 2026 net loss of $4.2M (9M: $13.0M) versus $13.6M (9M: $63.5M) in Q3 2025, representing significant improvement. Cash and investments totaled $67.1M as of September 30, 2026 (down from $76.3M at year-end 2025), sufficient to fund operations through 2027. R&D expenses fell to $0.2M (9M: $1.2M) from $9.1M (9M: $21.2M) year-over-year as the company pivots to an asset-focused subsidiary model; prior-year included $10M in in-process R&D write-offs.
Why this rating

Company reduced burn rate significantly and extended cash runway. At $83.4M market cap, $67.1M cash is healthy but core pipeline progress unclear; restructuring expenses subsiding.

View original filing on SEC.gov ↗ TIL · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.